Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder
Unknown status
Stanford University
Phase 2
1999-10-01
OBJECTIVES:
I. Evaluate the efficacy of intravenous versus oral pulse loading of clomipramine (CMI)
followed by a 12-week course of maintenance therapy in patients with obsessive compulsive
disorder.
Phase II Randomized Study of Intravenous Versus Oral Clomipramine in Patients With Obsessive Compulsive Disorder
Unknown status
National Center for Research Resources (NCRR)
Phase 2
1999-10-01
OBJECTIVES:
I. Evaluate the efficacy of intravenous versus oral pulse loading of clomipramine (CMI)
followed by a 12-week course of maintenance therapy in patients with obsessive compulsive
disorder.
Quetiapine Augmentation in Severe Obsessive Compulsive Disorder
Completed
AstraZeneca
Phase 3
2002-04-01
The purpose of the study is to evaluate the efficacy of quetiapine or placebo added to
baseline treatment of SSRI/clomipramine for the treatment of OCD in adult subjects.
Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment
Completed
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Phase 4
2007-05-01
This will be a controlled, randomized, double-blind and double-dummy study on the treatment
augmentation strategy for obsessive compulsive disorder patients non-respondent to first line
pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum
dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the
association of fluoxetine with clomipramine.
Using Drug Augmentation to Treat Obsessive Compulsive Disorder Patients Who Did Not Respond to Previous Treatment
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2007-05-01
This will be a controlled, randomized, double-blind and double-dummy study on the treatment
augmentation strategy for obsessive compulsive disorder patients non-respondent to first line
pharmacological treatment. The investigators will compare: fluoxetine maintenance at maximum
dosage for additional 12 weeks; the association of fluoxetine with quetiapine; and the
association of fluoxetine with clomipramine.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
